🧫
SAHA@LIPO-ANG2 therapeutic efficacy in 5xFAD mice
active
experiment
Created: 2026-04-10T22:46:49
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-9260f5b8-9e2c-41e6-9a6f-f42d7c505b38
🧫 Experiment Protocol
ValidationAlzheimer's diseaseHDAC4, NHE65xFAD transgenic miceproposed
This comprehensive in vivo experiment evaluated the therapeutic efficacy of angiopep2-conjugated nanoparticles containing vorinostat (SAHA@LIPO-ANG2) in 5xFAD transgenic mice, an established Alzheimer's disease model. The study assessed multiple outcome measures including amyloid-β burden reduction, neuroinflammation suppression, synaptic loss rescue, and cognitive function improvement. The nanoparticle formulation was designed to overcome blood-brain barrier penetration limitations of conventional HDAC inhibitors. This experiment provided crucial preclinical validation of the nanotherapeutic approach and demonstrated the translation of the mechanistic findings into functional therapeutic benefits in a relevant animal model of Alzheimer's disease.
PRIMARY OUTCOME
Cognitive deficit reversal and Aβ burden reduction
EXPECTED OUTCOMES
1. The intervention targeting HDAC4, NHE6 shifts Cognitive deficit reversal and Aβ burden reduction in the predicted direction relative to the matched control arm.
2. Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects.
3. The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.
SUCCESS CRITERIA
Significant reduction in Aβ plaques, decreased neuroinflammatory markers, restored synaptic proteins, improved performance in cognitive tests
PROTOCOL
1. Establish 5xFAD transgenic mice cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for HDAC4, NHE6, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure Cognitive deficit reversal and Aβ burden reduction together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5. Interpret results against the baseline study rationale: This comprehensive in vivo experiment evaluated the therapeutic efficacy of angiopep2-conjugated nanoparticles containing vorinostat (SAHA@LIPO-ANG2) in 5xFAD transgenic mice, an established Alzheimer's disease model. The study assessed multiple outcome measur
LINKED HYPOTHESES
h-seaad-v4-26ba859b· ACSL4-Driven Ferroptotic Priming in Disease-Associated Microgliah-4dd0d19b· LRP1-Dependent Tau Uptake Disruptionh-b234254c· TREM2-mediated microglial tau clearance enhancementh-55ef81c5· Extracellular Vesicle Biogenesis Modulationh-18a0fcc6· VCP-Mediated Autophagy Enhancement
Source: PMID 41933339 ↗
🧫 Experiment Extras
PATHWAY
HDAC4-NHE6-pH regulatory axis, amyloid clearance pathways
MARKET PRICE
$0.50
STATUS
proposed
Prediction Markets (1 direct, 0 via hypothesis — 1 total)
ACSL4-Driven Ferroptotic Priming in Disease-Associated MicrogliaYES 78% · Liq $100 · resolved▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.